Health X Platform Limited has informed the Exchange about Transcript

Health X Platform Limited (formerly Sastasundar Ventures) reported FY26 revenue of Rs 1,283 crores, up 18% YoY, with EBITDA loss narrowing sharply from Rs 79 crores to Rs 65 crores and PAT almost at breakeven (loss of Rs 1.4 crores vs Rs 133 crores loss last year). Q4 revenue grew 22% YoY to Rs 356 crores, with gross margins expanding to 7.3% from 5.9% and EBITDA margin improving to negative 5.5% from negative 10.3%. Management reiterated the long-term target of Rs 6,000 crore revenue by FY30 (Rs 4,000 cr from B2B Retailer Shakti + Rs 2,000 cr from B2C), with 5% EBITDA margin, 4% PAT, and ~40% ROE at scale. The company is investing Rs 234 crores capex (Rs 134 cr bank loans + Rs 100 cr treasury) to expand warehousing capacity to over 8 lakh sq ft and launched JITO private-label generics with 30-40% margins. A demerger of the finance division into separately listed Microsec Resources is also in progress, with 1 Microsec share for every 3 HealthX shares held.